Gustavo E. Velásquez, MD, MPH

Title(s)Assistant Professor, Medicine
SchoolSchool of Medicine
Address2540 23rd Street, #4901
San Francisco CA 94110
ORCID ORCID Icon0000-0003-1438-0692 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Stanford UniversityBAS2004
    Northwestern University Feinberg School of MedicineMD2009
    Harvard T.H. Chan School of Public HealthMPH2009Quantitative Methods and Infectious Disease Epidemiology
    Brigham and Women's HospitalResidency2013Internal Medicine
    Massachusetts General Hospital and Brigham and Women's HospitalFellowship2015Infectious Diseases

    Collapse Overview 
    Collapse Overview
    Dr. Velásquez is an Assistant Professor of Medicine in the Division of HIV, Infectious Diseases, and Global Medicine at the University of California, San Francisco. He is an infectious disease physician and clinical researcher focused on tuberculosis (TB) therapeutics. Based at the UCSF Center for Tuberculosis (tb.ucsf.edu), he works with the endTB consortium (endTB.org), the SMART4TB consortium (tbcenter.jhu.edu/smart4tb), and the AIDS Clinical Trials Group on Phase 2 and Phase 3 randomized controlled trials evaluating new shortened regimens for drug-susceptible and drug-resistant TB. He attends on the inpatient infectious diseases/HIV consult service and outpatient HIV and TB clinics at San Francisco General Hospital.

    Collapse Research 
    Collapse Research Activities and Funding
    A Phase 2C Randomized, Controlled, Open-Label Trial of Novel Shortened Regimens for the Treatment of Isoniazid-Monoresistant TB (IMR-TB)
    NIH R34AI179568Sep 1, 2024 - Aug 31, 2025
    Role: Principal Investigator
    Safety and tolerability of new and repurposed drugs for MDR-TB treatment
    NIH K08AI141740Feb 1, 2019 - Jan 31, 2024
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Bedaquiline, delamanid, linezolid and clofazimine for the treatment of rifampicin- and fluoroquinolone-resistant tuberculosis (endTB-Q): a Phase 3, open-label, multicentre, randomised, controlled, stratified, non-inferiority trial. SSRN [Preprint]. 2025. Guglielmetti L*, Khan U*, Velásquez G*, Gouillou M, Ali MH, Amjad S, Kamal F, Abubakirov A, Ardizzoni E, Baudin E, Bektasov S, Berry C, Bonnet M, Chavan V, Coutisson S, Dakenova Z, De Jong BC, Van Luong D, Ferlazzo G, Kirakosyan O, Kunda MK, Lachenal N, Lecca L, McIlleron HM, Mucching-Toscano S, Mulders W, Mushtaque H, Nahid P, Van Nguyen D, Nguyen NV, Oyewusi L, Motta I, Panda S, Patil S, Huu Pham T, Dat PT, Phan HTT, Phillips PP, Ruiz J, Rupasinghe P, Salahuddin N, Sanchez-Garavito E, Seung K, Tamirat M, Vargas D, Rich ML**, Varaine F**, Mitnick CD**, and endTB-Q Clinical Trial Team. View Publication.
    2. ACTG A5409 (RAD-TB): Study Protocol for a Phase 2 Randomized, Adaptive, Dose-Ranging, Open-Label Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis. Res Sq. 2025 Mar 26. Harrison L, Velasquez GE, Kempker RR, Imperial MZ, Nuermberger E, Dorman SE, Ignatius E, Granche J, Phillips PP, Furin J, Yang E, Foley C, Chiambah S, Rogers R, Grack AV, Roa J, Shenje J, Nerette S, Kanyama C, Kyeyune RB, Mendoza-Ticona A, Murtaugh W, Foraida S, Goth M, Vernon A, Dooley KE, Savic RM. PMID: 40195983; PMCID: PMC11975035.
      View in: PubMed   Mentions:
    3. Study protocol for a duration-randomized clinical trial to determine the optimal length of treatment for multidrug-resistant tuberculosis with a 5-drug regimen: The DRAMATIC trial. Contemp Clin Trials. 2025 Mar 08; 107875. Kaur P, Chaisson LH, Kiragu ZW, Buddadhumaruk P, Austin AF, Gao Y, Wirtz VJ, Arbeit RD, Fetalvero KB, Nguyen HB, Nguyen NV, Ha H, Eisenach K, Walter ND, Mitnick CD, Gler MTS, Phan H, Nahid P, Phillips PPJ, Horsburgh CR, Velásquez GE. PMID: 40064371.
      View in: PubMed   Mentions:
    4. Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysis. Lancet Child Adolesc Health. 2025 Feb; 9(2):100-111. Garcia-Prats AJ, Garcia-Cremades M, Cox V, Kredo T, Dunbar R, Schaaf HS, Seddon JA, Furin J, Achar J, Radke K, Sachs T, Abubakirov A, Ahmed S, Akkerman OW, Al Ani NA, Amanullah F, Ahmad N, Anderson LF, Asfaw M, Bango F, Bauer T, Becerra M, Boeree M, Brinkmann F, Brown R, Brust J, Campbell JR, Carvalho AC, Carvalho I, Cegielski JP, Centis R, Chan ED, Chauhan S, Chiang SS, Chan PC, D'Ambrosio L, Dalcolmo M, Daneilyan N, de Vries G, Draper HR, endTB Study Group, Fairlie L, Francis JR, Franke M, Gegia M, Restrepo CG, Guenther A, Gureva T, Haecker B, Harausz E, Hewison C, Hicks RM, Huerga H, Hughes J, Isaakidis P, Kadri SM, Khan MA, Kotrikadze T, Kuksa L, Lachenal N, Lange C, Lecca L, Lopez-Varela E, Lucena S, Mariandyshev A, Mattoo S, Mendez-Echevarria A, Migliori GB, Mitnick C, Mohr-Holland E, Mulanda W, Murzabakova T, Myrzalieve B, Ndjeka N, Niemann S, Ozere I, Padayatchi N, Parmar M, Parpieva N, Manzur-Ul-Alam M, Rybak N, Sachdeva KS, Salmon K, Santiago-Garcia B, Schaub D, Shah I, Shah S, Shah V, Sharma S, Shim TS, Shin S, Sinha A, Skrahina A, Solanki H, Solans BP, Soriano-Arandes A, Toktogonova A, van der Werf T, Velásquez GE, Williams B, Yim JJ, Savic R, Hesseling A. PMID: 39855750.
      View in: PubMed   Mentions:    Fields:    
    5. Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis. N Engl J Med. 2025 Jan 30; 392(5):468-482. Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Abubakirov A, Baudin E, Berikova E, Berry C, Bonnet M, Cellamare M, Chavan V, Cox V, Dakenova Z, de Jong BC, Ferlazzo G, Karabayev A, Kirakosyan O, Kiria N, Kunda M, Lachenal N, Lecca L, McIlleron H, Motta I, Toscano SM, Mushtaque H, Nahid P, Oyewusi L, Panda S, Patil S, Phillips PPJ, Ruiz J, Salahuddin N, Garavito ES, Seung KJ, Ticona E, Trippa L, Vasquez DEV, Wasserman S, Rich ML, Varaine F, Mitnick CD, endTB Clinical Trial Team. PMID: 39879593; PMCID: PMC7617355.
      View in: PubMed   Mentions:    Fields:    Translation:CTClinical Trials
    6. Person-centred language for describing stratified approaches to TB treatment. IJTLD Open. 2025 Jan; 2(1):56-58. Nash M, Deluca A, Lessem E, West N, McKenna L, McConnell EV, Angami K, Herrera R, Makone A, Velásquez GE, Chaisson RE, Phillips PPJ. PMID: 39802229; PMCID: PMC11724526.
      View in: PubMed   Mentions:
    7. Pyrazinamide Safety, Efficacy, and Dosing for Treating Drug-Susceptible Pulmonary Tuberculosis: A Phase 3, Randomized Controlled Clinical Trial. Am J Respir Crit Care Med. 2024 Dec 01; 210(11):1358-1369. Xu AY, Velásquez GE, Zhang N, Chang VK, Phillips PPJ, Nahid P, Dorman SE, Kurbatova EV, Whitworth WC, Sizemore E, Bryant K, Carr W, Brown NE, Engle ML, Nhung NV, Nsubuga P, Diacon A, Dooley KE, Chaisson RE, Swindells S, Savic RM. PMID: 39012226; PMCID: PMC11622436.
      View in: PubMed   Mentions: 1     Fields:    Translation:CTClinical Trials
    8. Risk-stratified treatment for drug-susceptible pulmonary tuberculosis. Nat Commun. 2024 Oct 30; 15(1):9400. Chang VK, Imperial MZ, Phillips PPJ, Velásquez GE, Nahid P, Vernon A, Kurbatova EV, Swindells S, Chaisson RE, Dorman SE, Johnson JL, Weiner M, Sizemore EE, Whitworth W, Carr W, Bryant KE, Burton D, Dooley KE, Engle M, Nsubuga P, Diacon AH, Nhung NV, Dawson R, Savic RM, AIDS Clinical Trial Group, Tuberculosis Trials Consortium. PMID: 39477924; PMCID: PMC11526018.
      View in: PubMed   Mentions:    Fields:    Translation:CTClinical Trials
    9. Percent of lung involved in disease on chest X-ray predicts unfavorable treatment outcome in pulmonary tuberculosis. medRxiv. 2024 Aug 20. Ghanem M, Srivastava R, Ektefaie Y, Hoppes D, Rosenfeld G, Yaniv Z, Grinev A, Xu AY, Yang E, Velásquez GE, Harrison L, Rosenthal A, Savic RM, Jacobson KR, Farhat MR. PMID: 39228708; PMCID: PMC11370523.
      View in: PubMed   Mentions:
    10. Pharmacokinetic-Pharmacodynamic Evidence From a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis. Clin Infect Dis. 2024 06 14; 78(6):1680-1689. Ngo HX, Xu AY, Velásquez GE, Zhang N, Chang VK, Kurbatova EV, Whitworth WC, Sizemore E, Bryant K, Carr W, Weiner M, Dooley KE, Engle M, Dorman SE, Nahid P, Swindells S, Chaisson RE, Nsubuga P, Lourens M, Dawson R, Savic RM. PMID: 38462673; PMCID: PMC11175687.
      View in: PubMed   Mentions:    Fields:    Translation:CTClinical Trials
    11. Experience With Four-Month Rifapentine and Moxifloxacin-Based Tuberculosis Treatment in San Francisco. Open Forum Infect Dis. 2024 Apr; 11(4):ofae178. Louie JK, Agraz-Lara R, Velásquez GE, Phillips A, Szumowski JD. PMID: 38634108; PMCID: PMC11021345.
      View in: PubMed   Mentions: 1  
    12. Nine-month, all-oral regimens for rifampin-resistant tuberculosis. medRxiv [Preprint]. 2024; 2024.01.29.24301679. Guglielmetti L*, Khan U*, Velásquez GE*, Gouillou M, Abubakirov A, Baudin E, Berikova E, Berry C, Bonnet M, Cellamare M, Chavan V, Cox V, Dakenova Z, De Jong BC, Ferlazzo G, Karabayev A, Kirakosyan O, Kiria N, Kunda M, Lachenal N, Lecca L, McIlleron H, Motta I, Mucching-Toscano S, Mushtaque H, Nahid P, Oyewusi L, Panda S, Patil S, Phillips P, Ruiz J, Salahuddin N, Sanchez-Garavito E, Seung KJ, Ticona E, Trippa L, Vargas D, Wasserman S, Rich ML, Varaine F**, Mitnick CD**. View Publication.
    13. Standards for clinical trials for treating TB. Int J Tuberc Lung Dis. 2023 Dec 01; 27(12):885-898. du Cros P, Greig J, Alffenaar JC, Cross GB, Cousins C, Berry C, Khan U, Phillips PPJ, Velásquez GE, Furin J, Spigelman M, Denholm JT, Thi SS, Tiberi S, Huang GKL, Marks GB, Turkova A, Guglielmetti L, Chew KL, Nguyen HT, Ong CWM, Brigden G, Singh KP, Motta I, Lange C, Seddon JA, Nyang'wa BT, Maug AKJ, Gler MT, Dooley KE, Quelapio M, Tsogt B, Menzies D, Cox V, Upton CM, Skrahina A, McKenna L, Horsburgh CR, Dheda K, Marais BJ. PMID: 38042969; PMCID: PMC10719894.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    14. Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial. Trials. 2023 Nov 30; 24(1):773. Patil SB, Tamirat M, Khazhidinov K, Ardizzoni E, Atger M, Austin A, Baudin E, Bekhit M, Bektasov S, Berikova E, Bonnet M, Caboclo R, Chaudhry M, Chavan V, Cloez S, Coit J, Coutisson S, Dakenova Z, De Jong BC, Delifer C, Demaisons S, Do JM, Dos Santos Tozzi D, Ducher V, Ferlazzo G, Gouillou M, Khan U, Kunda M, Lachenal N, LaHood AN, Lecca L, Mazmanian M, McIlleron H, Moreau M, Moschioni M, Nahid P, Osso E, Oyewusi L, Panda S, Pâquet A, Thuong Huu P, Pichon L, Rich ML, Rupasinghe P, Salahuddin N, Sanchez Garavito E, Seung KJ, Velásquez GE, Vallet M, Varaine F, Yuya-Septoh FJ, Mitnick CD, Guglielmetti L. PMID: 38037119; PMCID: PMC10688049.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    15. An activist’s guide to shorter treatment for drug-resistant tuberculosis. 2023. McKenna L, Branigan D, Deborggraeve S, Frick M, Furin J, Galarza J, Gebhard A, Gupta S, Kaiser B, de Kruijf-Carter I, Kumar B, Mabote L, Mbenga M, Mirzayev F, Moses GK, Nguyen L, Nyang’wa BT, Pak S, Perrin C, Salazar-Austin N, Sari AH, Seidel S, Velásquez G, Waite R, Waning B, Wares F. View Publication.
    16. Scientific advances and the end of tuberculosis: a report from the Lancet Commission on Tuberculosis. Lancet. 2023 10 21; 402(10411):1473-1498. Reid M, Agbassi YJP, Arinaminpathy N, Bercasio A, Bhargava A, Bhargava M, Bloom A, Cattamanchi A, Chaisson R, Chin D, Churchyard G, Cox H, Denkinger CM, Ditiu L, Dowdy D, Dybul M, Fauci A, Fedaku E, Gidado M, Harrington M, Hauser J, Heitkamp P, Herbert N, Herna Sari A, Hopewell P, Kendall E, Khan A, Kim A, Koek I, Kondratyuk S, Krishnan N, Ku CC, Lessem E, McConnell EV, Nahid P, Oliver M, Pai M, Raviglione M, Ryckman T, Schäferhoff M, Silva S, Small P, Stallworthy G, Temesgen Z, van Weezenbeek K, Vassall A, Velásquez GE, Venkatesan N, Yamey G, Zimmerman A, Jamison D, Swaminathan S, Goosby E. PMID: 37716363.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    17. Recent advances in the treatment of tuberculosis. Clin Microbiol Infect. 2024 Sep; 30(9):1107-1114. Motta I, Boeree M, Chesov D, Dheda K, Günther G, Horsburgh CR, Kherabi Y, Lange C, Lienhardt C, McIlleron HM, Paton NI, Stagg HR, Thwaites G, Udwadia Z, Van Crevel R, Velásquez GE, Wilkinson RJ, Guglielmetti L, Study group on Mycobacteria (ESGMYC) of the European Society of Clinical Microbiology and Infectious. PMID: 37482332.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    18. Respiratory, Cardiac, and Neuropsychiatric Manifestations of Postacute Sequelae of Coronavirus Disease 2019 in Lima, Peru. Open Forum Infect Dis. 2023 Jul; 10(7):ofad320. Rahman RS, Tovar MA, Peinado J, Palomino JS, Ramirez C, Llanos-Zavalaga F, Peralta E, Valderrama G, Ramos Cordova LB, Sanchez Cortez LI, Rodriguez G, LaHood AN, Franke MF, Mitnick CD, Lecca L, Velásquez GE. PMID: 37496609; PMCID: PMC10368202.
      View in: PubMed   Mentions:
    19. Promise and Peril of Pretomanid-Rifamycin Regimens for Drug-susceptible Tuberculosis. Am J Respir Crit Care Med. 2023 04 01; 207(7):816-818. Velásquez GE, Nahid P. PMID: 36630555; PMCID: PMC10111973.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    20. Low detection rate of RT-PCR-confirmed COVID-19 using IgM/IgG rapid antibody tests in a large community sample in Lima, Peru. BMC Infect Dis. 2023 Feb 02; 23(1):62. Law S, Tovar MA, Franke MF, Calderon R, Palomino S, Valderrama G, Llanos F, Velásquez GE, Mitnick CD, Lecca L. PMID: 36732690; PMCID: PMC9893955.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    21. Clinical Outcomes of Individuals with COVID-19 and Tuberculosis during the Pre-Vaccination Period of the Pandemic: A Systematic Review. J Clin Med. 2022 Sep 26; 11(19). Jhaveri TA, Fung C, LaHood AN, Lindeborg A, Zeng C, Rahman R, Bain PA, Velásquez GE, Mitnick CD. PMID: 36233523; PMCID: PMC9570663.
      View in: PubMed   Mentions: 4  
    22. Diagnostic Performance Assessment of Saliva RT-PCR and Nasopharyngeal Antigen for the Detection of SARS-CoV-2 in Peru. Microbiol Spectr. 2022 08 31; 10(4):e0086122. Calderón RI, Jhaveri TA, Tovar MA, Palomino JS, Barreda NN, Sanabria OM, Peinado J, Ramirez C, Llanos Zavalaga LF, Valderrama G, Franke MF, Mitnick CD, Lecca L, Velásquez GE. PMID: 35867471; PMCID: PMC9430815.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCellsPHPublic Health
    23. Prevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies Among Market and City Bus Depot Workers in Lima, Peru. Clin Infect Dis. 2022 01 29; 74(2):343-346. Tovar M, Peinado J, Palomino S, Llanos F, Ramírez C, Valderrama G, Calderón RI, Williams RB, Velásquez GE, Mitnick CD, Franke MF, Lecca L. PMID: 33881476; PMCID: PMC8083218.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    24. Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial. Trials. 2021 Sep 25; 22(1):651. Guglielmetti L, Ardizzoni E, Atger M, Baudin E, Berikova E, Bonnet M, Chang E, Cloez S, Coit JM, Cox V, de Jong BC, Delifer C, Do JM, Tozzi DDS, Ducher V, Ferlazzo G, Gouillou M, Khan A, Khan U, Lachenal N, LaHood AN, Lecca L, Mazmanian M, McIlleron H, Moschioni M, O'Brien K, Okunbor O, Oyewusi L, Panda S, Patil SB, Phillips PPJ, Pichon L, Rupasinghe P, Rich ML, Saluhuddin N, Seung KJ, Tamirat M, Trippa L, Cellamare M, Velásquez GE, Wasserman S, Zimetbaum PJ, Varaine F, Mitnick CD. PMID: 34563240; PMCID: PMC8465691.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    25. Disparities in SARS-CoV-2 Vaccination-to-Infection Risk During the COVID-19 Pandemic in Massachusetts. JAMA Health Forum. 2021 09; 2(9):e212666. Dryden-Peterson S, Velásquez GE, Stopka TJ, Davey S, Gandhi RT, Lockman S, Ojikutu BO. PMID: 35977180; PMCID: PMC8796904.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCellsPHPublic Health
    26. Disparities in SARS-CoV-2 Vaccination-to-Infection Risk, Massachusetts 2020-2021. medRxiv [Preprint]. 2021; 2021.04.14.21255467.2021. Dryden-Peterson S, Velásquez GE, Stopka TJ, Davey S, Gandhi RT, Lockman S, Ojikutu BO. View Publication.
    27. Disparities in SARS-CoV-2 Testing in Massachusetts During the COVID-19 Pandemic. JAMA Netw Open. 2021 02 01; 4(2):e2037067. Dryden-Peterson S, Velásquez GE, Stopka TJ, Davey S, Lockman S, Ojikutu BO. PMID: 33560423; PMCID: PMC7873783.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCellsPHPublic Health
    28. SARS-CoV-2 Testing Disparities in Massachusetts. medRxiv. 2020 Nov 04. Dryden-Peterson S, Velásquez GE, Stopka TJ, Davey S, Lockman S, Ojikutu B. PMID: 33173919; PMCID: PMC7654915.
      View in: PubMed   Mentions:
    29. Omadacycline for the Treatment of Mycobacterium abscessus Disease: A Case Series. Open Forum Infect Dis. 2020 Oct; 7(10):ofaa415. Pearson JC, Dionne B, Richterman A, Vidal SJ, Weiss Z, Velásquez GE, Marty FM, Sax PE, Yawetz S. PMID: 33094118; PMCID: PMC7566545.
      View in: PubMed   Mentions: 24  
    30. Delayed Relapse of Paracoccidioidomycosis in the Central Nervous System: A Case Report. Open Forum Infect Dis. 2020 Apr; 7(4):ofaa077. Rahman R, Davies L, Mohareb AM, Peçanha-Pietrobom PM, Patel NJ, Solomon IH, Meredith DM, Tsai HK, Guenette JP, Bhattacharyya S, Urday S, Velásquez GE. PMID: 32258208; PMCID: PMC7112725.
      View in: PubMed   Mentions: 4  
    31. The fourth national anti-tuberculosis drug resistance survey in Peru. Int J Tuberc Lung Dis. 2020 02 01; 24(2):207-213. Quispe N, Asencios L, Obregon C, Velásquez GE, Mitnick CD, Lindeborg M, Jave H, Solari L. PMID: 32127106; PMCID: PMC7325691.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    32. Quantitative assessment of the activity of antituberculosis drugs and regimens. Expert Rev Anti Infect Ther. 2019 06; 17(6):449-457. Chirehwa MT, Velásquez GE, Gumbo T, McIlleron H. PMID: 31144539; PMCID: PMC6581212.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    33. Reply to te Brake et al.: Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis. Am J Respir Crit Care Med. 2019 05 01; 199(9):1167-1168. Velásquez GE, Brooks MB, Coit JM, Sánchez Garavito E, Calderón RI, Jiménez J, Tintaya K, Peloquin CA, Osso E, Lecca L, Davies GR, Mitnick CD. PMID: 30645140; PMCID: PMC6515881.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    34. Outcomes of a Career Development Program for Underrepresented Minority Investigators in the AIDS Clinical Trials Group. Open Forum Infect Dis. 2019 Mar; 6(3):ofz069. Velásquez GE, Huaman MA, Powell KR, Cohn SE, Swaminathan S, Outlaw M, Schulte G, McNeil Q, Currier JS, Del Rio C, Castillo-Mancilla J. PMID: 30895207; PMCID: PMC6419986.
      View in: PubMed   Mentions: 3  
    35. Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis. A Randomized Controlled Trial. Am J Respir Crit Care Med. 2018 09 01; 198(5):657-666. Velásquez GE, Brooks MB, Coit JM, Pertinez H, Vargas Vásquez D, Sánchez Garavito E, Calderón RI, Jiménez J, Tintaya K, Peloquin CA, Osso E, Tierney DB, Seung KJ, Lecca L, Davies GR, Mitnick CD. PMID: 29954183; PMCID: PMC6118011.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCellsCTClinical Trials
    36. Making up the difference: ensuring the bioequivalence of fixed-dose combinations for tuberculosis. Int J Tuberc Lung Dis. 2018 05 01; 22(5):473-474. Velásquez GE, Davies GR, Mitnick CD. PMID: 29663947; PMCID: PMC5940349.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    37. A Case of Disseminated Histoplasmosis in a Patient with Rheumatoid Arthritis on Abatacept. J Gen Intern Med. 2018 05; 33(5):769-772. Jain N, Doyon JB, Lazarus JE, Schaefer IM, Johncilla ME, Agoston AT, Dalal AK, Velásquez GE. PMID: 29532302; PMCID: PMC5910370.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    38. Prevalence of pyrazinamide resistance and Wayne assay performance analysis in a tuberculosis cohort in Lima, Peru. Int J Tuberc Lung Dis. 2017 08 01; 21(8):894-901. Calderón RI, Velásquez GE, Becerra MC, Zhang Z, Contreras CC, Yataco RM, Galea JT, Lecca LW, Kritski AL, Murray MB, Mitnick CD. PMID: 28786798; PMCID: PMC5555119.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    39. Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis. Antimicrob Agents Chemother. 2017 08; 61(8). Peloquin CA, Velásquez GE, Lecca L, Calderón RI, Coit J, Milstein M, Osso E, Jimenez J, Tintaya K, Sanchez Garavito E, Vargas Vasquez D, Mitnick CD, Davies G. PMID: 28559269; PMCID: PMC5527578.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCellsCTClinical Trials
    40. Nutritional Status and Tuberculosis Risk in Adult and Pediatric Household Contacts. PLoS One. 2016; 11(11):e0166333. Aibana O, Acharya X, Huang CC, Becerra MC, Galea JT, Chiang SS, Contreras C, Calderon R, Yataco R, Velásquez GE, Tintaya K, Jimenez J, Lecca L, Murray MB. PMID: 27835678; PMCID: PMC5105945.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansPHPublic Health
    41. Pyrazinamide Resistance Assays and Two-Month Sputum Culture Status in Patients with Multidrug-Resistant Tuberculosis. Antimicrob Agents Chemother. 2016 11; 60(11):6766-6773. Velásquez GE, Calderon RI, Mitnick CD, Becerra MC, Huang CC, Zhang Z, Contreras CC, Yataco RM, Galea JT, Lecca LW, Murray MB. PMID: 27600032; PMCID: PMC5075084.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    42. Novel Ordered Stepped-Wedge Cluster Trial Designs for Detecting Ebola Vaccine Efficacy Using a Spatially Structured Mathematical Model. PLoS Negl Trop Dis. 2016 08; 10(8):e0004866. Diakite I, Mooring EQ, Velásquez GE, Murray MB. PMID: 27509037; PMCID: PMC4979980.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic Health
    43. Impact of HIV on mortality among patients treated for tuberculosis in Lima, Peru: a prospective cohort study. BMC Infect Dis. 2016 Feb 01; 16:45. Velásquez GE, Cegielski JP, Murray MB, Yagui MJ, Asencios LL, Bayona JN, Bonilla CA, Jave HO, Yale G, Suárez CZ, Sanchez E, Rojas C, Atwood SS, Contreras CC, Santa Cruz J, Shin SS. PMID: 26831140; PMCID: PMC4736097.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    44. Time From Infection to Disease and Infectiousness for Ebola Virus Disease, a Systematic Review. Clin Infect Dis. 2015 Oct 01; 61(7):1135-40. Velásquez GE, Aibana O, Ling EJ, Diakite I, Mooring EQ, Murray MB. PMID: 26129757; PMCID: PMC4560911.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCellsPHPublic Health
    45. Improving outcomes for multidrug-resistant tuberculosis: aggressive regimens prevent treatment failure and death. Clin Infect Dis. 2014 Jul 01; 59(1):9-15. Velásquez GE, Becerra MC, Gelmanova IY, Pasechnikov AD, Yedilbayev A, Shin SS, Andreev YG, Yanova G, Atwood SS, Mitnick CD, Franke MF, Rich ML, Keshavjee S. PMID: 24729493; PMCID: PMC4305127.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCells
    46. Targeted drug-resistance testing strategy for multidrug-resistant tuberculosis detection, Lima, Peru, 2005-2008. Emerg Infect Dis. 2011 Mar; 17(3):432-40. Velásquez GE, Yagui M, Cegielski JP, Asencios L, Bayona J, Bonilla C, Jave HO, Yale G, Suárez C, Atwood S, Contreras CC, Shin SS. PMID: 21392434; PMCID: PMC3166030.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCellsPHPublic Health
    Gustavo's Networks
    Concepts (113)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (14)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-9-g3adcefa5 on PROFILES-PWEB04.

    Copyright © The Regents of the University of California.